Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Terminated 1Completed 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 2

Conditions

Carcinoma, Renal Cell 6Colorectal Neoplasms 3Solid Tumors 2Breast Neoplasms 2Triple Negative Breast Neoplasms 1Gastrointestinal Neoplasms 1Disease Progression 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Hepatocellular 1Advanced Solid Tumors 1

Interventions

Trastuzumab 209Paclitaxel 187Fulvestrant 161Capecitabine 150Docetaxel 136Letrozole 127exemestane 92palbociclib 76Anastrozole 75Cyclophosphamide 71Lapatinib 69Gemcitabine 66Bevacizumab 66pertuzumab 61ribociclib 60pembrolizumab 60Carboplatin 59abemaciclib 53eribulin 48Doxorubicin 45Vinorelbine 41Everolimus 41Ado-Trastuzumab Emtansine 41Tamoxifen 40130-nm albumin-bound paclitaxel 34Injections 31trastuzumab deruxtecan 30Albumin-Bound Paclitaxel 26olaparib 24Alpelisib 24

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Breast Neoplasms × tivozanib × Clear all
NCT01745367 2020-10-27

BATON-BC

AVEO Pharmaceuticals, Inc.

Phase 2 Terminated
30 enrolled 10 charts
Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT00717340 2012-06-28

A Phase 1b/2a, Open-Label, Multi-Center Study of Tivozanib (AV-951) in Combination With Paclitaxel in Subjects With Advanced or Metastatic Breast Cancer

AVEO Pharmaceuticals, Inc.

Phase 1 Completed
18 enrolled
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡